Colleen Kusy
Stock Analyst at Baird
(1.53)
# 3,525
Out of 5,124 analysts
54
Total ratings
36.96%
Success rate
-5.35%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colleen Kusy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Downgrades: Neutral | $924 → $858 | $840.95 | +2.03% | 1 | Dec 18, 2025 | |
| NUVL Nuvalent | Maintains: Outperform | $112 → $158 | $100.59 | +57.07% | 3 | Nov 18, 2025 | |
| COGT Cogent Biosciences | Maintains: Neutral | $14 → $34 | $35.52 | -4.28% | 1 | Nov 11, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $50 → $52 | $25.12 | +107.01% | 13 | Oct 31, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Outperform | $17 → $24 | $12.14 | +97.78% | 5 | Oct 3, 2025 | |
| CLYM Climb Bio | Initiates: Outperform | $9 | $4.00 | +125.00% | 1 | Aug 15, 2025 | |
| ELVN Enliven Therapeutics | Maintains: Outperform | $40 → $52 | $15.40 | +237.66% | 3 | Jun 16, 2025 | |
| AGEN Agenus | Maintains: Neutral | $4 → $6 | $3.14 | +91.08% | 4 | Jun 4, 2025 | |
| OCS Oculis Holding AG | Maintains: Outperform | $37 → $41 | $19.97 | +105.31% | 4 | Mar 13, 2025 | |
| CHRS Coherus Oncology | Maintains: Outperform | $4 → $6 | $1.43 | +320.46% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $65 | $32.76 | +98.41% | 2 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $100 → $75 | $28.93 | +159.25% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $27 → $25 | $8.18 | +205.62% | 1 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $255 → $210 | $7.36 | +2,753.26% | 1 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $2.73 | +1,145.42% | 5 | Apr 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $230 | $3.74 | +6,049.73% | 1 | Nov 2, 2021 |
argenx SE
Dec 18, 2025
Downgrades: Neutral
Price Target: $924 → $858
Current: $840.95
Upside: +2.03%
Nuvalent
Nov 18, 2025
Maintains: Outperform
Price Target: $112 → $158
Current: $100.59
Upside: +57.07%
Cogent Biosciences
Nov 11, 2025
Maintains: Neutral
Price Target: $14 → $34
Current: $35.52
Upside: -4.28%
Apellis Pharmaceuticals
Oct 31, 2025
Maintains: Outperform
Price Target: $50 → $52
Current: $25.12
Upside: +107.01%
Ocular Therapeutix
Oct 3, 2025
Maintains: Outperform
Price Target: $17 → $24
Current: $12.14
Upside: +97.78%
Climb Bio
Aug 15, 2025
Initiates: Outperform
Price Target: $9
Current: $4.00
Upside: +125.00%
Enliven Therapeutics
Jun 16, 2025
Maintains: Outperform
Price Target: $40 → $52
Current: $15.40
Upside: +237.66%
Agenus
Jun 4, 2025
Maintains: Neutral
Price Target: $4 → $6
Current: $3.14
Upside: +91.08%
Oculis Holding AG
Mar 13, 2025
Maintains: Outperform
Price Target: $37 → $41
Current: $19.97
Upside: +105.31%
Coherus Oncology
Dec 5, 2024
Maintains: Outperform
Price Target: $4 → $6
Current: $1.43
Upside: +320.46%
Nov 13, 2024
Maintains: Outperform
Price Target: $50 → $65
Current: $32.76
Upside: +98.41%
Aug 14, 2024
Maintains: Neutral
Price Target: $100 → $75
Current: $28.93
Upside: +159.25%
Mar 12, 2024
Reiterates: Outperform
Price Target: $27 → $25
Current: $8.18
Upside: +205.62%
Aug 5, 2022
Maintains: Outperform
Price Target: $255 → $210
Current: $7.36
Upside: +2,753.26%
Apr 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $2.73
Upside: +1,145.42%
Nov 2, 2021
Initiates: Outperform
Price Target: $230
Current: $3.74
Upside: +6,049.73%